IBDEI0FN ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7533,1,3,0)
 ;;=3^One Eye-Severe/Oth Eye-Near Total
 ;;^UTILITY(U,$J,358.3,7533,1,4,0)
 ;;=4^369.13
 ;;^UTILITY(U,$J,358.3,7533,2)
 ;;=^268873
 ;;^UTILITY(U,$J,358.3,7534,0)
 ;;=369.14^^49^558^81
 ;;^UTILITY(U,$J,358.3,7534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7534,1,3,0)
 ;;=3^One Eye-Severe/Oth Eye-Profound
 ;;^UTILITY(U,$J,358.3,7534,1,4,0)
 ;;=4^369.14
 ;;^UTILITY(U,$J,358.3,7534,2)
 ;;=^268874
 ;;^UTILITY(U,$J,358.3,7535,0)
 ;;=369.22^^49^558^102
 ;;^UTILITY(U,$J,358.3,7535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7535,1,3,0)
 ;;=3^Severe Impairment,Both Eyes
 ;;^UTILITY(U,$J,358.3,7535,1,4,0)
 ;;=4^369.22
 ;;^UTILITY(U,$J,358.3,7535,2)
 ;;=^268882
 ;;^UTILITY(U,$J,358.3,7536,0)
 ;;=369.60^^49^558^6
 ;;^UTILITY(U,$J,358.3,7536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7536,1,3,0)
 ;;=3^Blindness,One Eye Only
 ;;^UTILITY(U,$J,358.3,7536,1,4,0)
 ;;=4^369.60
 ;;^UTILITY(U,$J,358.3,7536,2)
 ;;=^268880
 ;;^UTILITY(U,$J,358.3,7537,0)
 ;;=369.9^^49^558^115
 ;;^UTILITY(U,$J,358.3,7537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7537,1,3,0)
 ;;=3^Visual Loss NOS
 ;;^UTILITY(U,$J,358.3,7537,1,4,0)
 ;;=4^369.9
 ;;^UTILITY(U,$J,358.3,7537,2)
 ;;=^126769
 ;;^UTILITY(U,$J,358.3,7538,0)
 ;;=377.61^^49^558^20
 ;;^UTILITY(U,$J,358.3,7538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7538,1,3,0)
 ;;=3^D/O Pathways w/ Neoplasm
 ;;^UTILITY(U,$J,358.3,7538,1,4,0)
 ;;=4^377.61
 ;;^UTILITY(U,$J,358.3,7538,2)
 ;;=^269241
 ;;^UTILITY(U,$J,358.3,7539,0)
 ;;=379.02^^49^558^68
 ;;^UTILITY(U,$J,358.3,7539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7539,1,3,0)
 ;;=3^Nodular Episcleritis
 ;;^UTILITY(U,$J,358.3,7539,1,4,0)
 ;;=4^379.02
 ;;^UTILITY(U,$J,358.3,7539,2)
 ;;=^269285
 ;;^UTILITY(U,$J,358.3,7540,0)
 ;;=379.07^^49^558^90
 ;;^UTILITY(U,$J,358.3,7540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7540,1,3,0)
 ;;=3^Posterior Scleritis
 ;;^UTILITY(U,$J,358.3,7540,1,4,0)
 ;;=4^379.07
 ;;^UTILITY(U,$J,358.3,7540,2)
 ;;=^269295
 ;;^UTILITY(U,$J,358.3,7541,0)
 ;;=379.92^^49^558^106
 ;;^UTILITY(U,$J,358.3,7541,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7541,1,3,0)
 ;;=3^Swelling/Mass of Eye
 ;;^UTILITY(U,$J,358.3,7541,1,4,0)
 ;;=4^379.92
 ;;^UTILITY(U,$J,358.3,7541,2)
 ;;=^269334
 ;;^UTILITY(U,$J,358.3,7542,0)
 ;;=379.93^^49^558^94
 ;;^UTILITY(U,$J,358.3,7542,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7542,1,3,0)
 ;;=3^Redness/Discharge of Eye
 ;;^UTILITY(U,$J,358.3,7542,1,4,0)
 ;;=4^379.93
 ;;^UTILITY(U,$J,358.3,7542,2)
 ;;=^104154
 ;;^UTILITY(U,$J,358.3,7543,0)
 ;;=379.99^^49^558^86
 ;;^UTILITY(U,$J,358.3,7543,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7543,1,3,0)
 ;;=3^Oth Ill-Defined Eye D/O
 ;;^UTILITY(U,$J,358.3,7543,1,4,0)
 ;;=4^379.99
 ;;^UTILITY(U,$J,358.3,7543,2)
 ;;=^269335
 ;;^UTILITY(U,$J,358.3,7544,0)
 ;;=555.9^^49^558^95
 ;;^UTILITY(U,$J,358.3,7544,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7544,1,3,0)
 ;;=3^Regional Enteritis,Unspec
 ;;^UTILITY(U,$J,358.3,7544,1,4,0)
 ;;=4^555.9
 ;;^UTILITY(U,$J,358.3,7544,2)
 ;;=^29356
 ;;^UTILITY(U,$J,358.3,7545,0)
 ;;=696.1^^49^558^93
 ;;^UTILITY(U,$J,358.3,7545,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7545,1,3,0)
 ;;=3^Psoriasis
 ;;^UTILITY(U,$J,358.3,7545,1,4,0)
 ;;=4^696.1
 ;;^UTILITY(U,$J,358.3,7545,2)
 ;;=^271917
 ;;^UTILITY(U,$J,358.3,7546,0)
 ;;=709.2^^49^558^39
 ;;^UTILITY(U,$J,358.3,7546,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7546,1,3,0)
 ;;=3^Facial Scar
 ;;^UTILITY(U,$J,358.3,7546,1,4,0)
 ;;=4^709.2
 ;;^UTILITY(U,$J,358.3,7546,2)
 ;;=^108131
 ;;^UTILITY(U,$J,358.3,7547,0)
 ;;=710.0^^49^558^60
